Timeline
June 2017
Began exporting Lactase to Europe
March 2017
Acquired Sungwun Bio Co.
Jan 2017
Awarded patent for mutanase, an oral care enzyme
July 2016
Recognized as a Global Excellent Company by Daejeon Metropolitan City, KAIST and the University of Texas at Austin
June 2016
Completed the pilot tests for new lipases for active pharmaceutical ingredient (API) production and biodiesel production
May 2016
Constructed new production facility at company headquarters in Daejeon to produce specialty enzymes
Food Safety System Certification(FSSC 22000)
Apr 2016
Completed the pilot test for the world's first bio-retinol production
Sep 2015
Secured lactase supply contract with Company L
May 2015
Became publicly traded company listed on KOSDAQ
Aug 2014
Began production of Katalase S 350L in GenoFocus' Chinese facility
May 2014
Letter of Understanding and Non Disclosure Agreement Signed with Company L
Sep 2013
Built plant in Jeonbuk Institute for Bioindustry to produce food enzymes
Aug 2013
Launched Katalase S 350L for decomposing H2O2 used in semiconductor manufacturing
May 2012
Established wholly-owned subsidiary in China (GenoFocus Biotechnology Ltd.)
Dec 2011
Began collaboration with LG Healthcare to develop an oral care enzyme
Nov 2011
Launched Katalase S for decomposing H2O2 used in textile production
Oct 2011
Licensed galacto-oligosaccharide synthesis (GOS) production technology to Company Q in China
Dec 2010
Developed and launched Lactase, ideal for use in GOS mass production
Nov 2010
Completed production technology for TL Lipase for use in API production
Completed process development for mass production of Catalase
Sep 2009
Signed NDA with Company I to develop Lactase for GOS mass production usage
Dec 2008
South Korea's Defense Acquisition Program Administration appointed GenoFocus for a dual use (military and civil) technology development project to produce eco-friendly decontaminants for chemical and biological agents
Nov 2008
NDA signed with a global pharmaceutical company to optimize lipase for producing next-generation anticonvulsant drugs
Oct 2004
Dr. Eui-Joong Kim appointed as GenoFocus' CEO
Dr. Jae-Gu Pan becomes GenoFocus' CTO
Dec 2002
Designated as an INNO-BIZ enterprise
May 2001
Designated as a National Research Laboratory to develop ‘Microbial Display technology’
Feb 2001
Certification of Venture Business
Apr 2000
Incorporated through a KRIBB project by Founder and former CEO and current CTO Dr. Jae-Gu Pan